Jan Van den Bossche

DR.IR., (Principal Investigator)

20082021

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Specialisation

Jan Van den Bossche completed his Master in Bioscience Engineering in 2006 at Vrije Universiteit Brussel (Belgium), specializing in Cell and Gene Biotechnology and Immunology.

Throughout his career he has been fascinated by the regulation, plasticity and function of myeloid cell subsets in the context of distinct Western diseases. 

He obtained his PhD in 2011 at the Myeloid Cell Immunology lab, headed by Prof. Jo Van Ginderachter at VIB, Brussels, Belgium. During this period, he identified E-cadherin as a new marker for M2 macrophages and described polyamines as crucial regulators of macrophages. 

Jan joined to the group of Prof. Menno de Winther at the Academic Medical Center (AMC) of Amsterdam in 2012. As a starting post-doctoral researcher, Jan Van den Bossche obtained a personal junior postdoc grant from Netherlands Heart Foundation (Hartstichting) to study epigenetics as a regulator of macrophages during atherosclerosis. Obtaining a VENI grant from NWO allowed him to start an independent research line, investigating the metabolic regulation of macrophages. 

At the end of 2017, Jan became PI at the Department of Molecular Cell Biology and Immunology where his group investigates how targeting macrophage metabolism can be applied to improve their function and disease outcome.

As an Assistent Professor, now leads the Translational Macrophage Immunometabolism group "Immunometlab" and specializes in the metabolic profiling and targeting of macrophages and other immune cells, particularly in the context of cancer and cardiometabolic disease.

Reseach topics include immunometabolites, metabolic immune-cancer interactions, metabolic enzymes (including ACLY; ATP citrate lyase), and metabolic profiling techniques include extracellular flux analysis (Seahorse), metabolomics, Cytation multi-mode imaging plate reader, transcriptomics, and cytometry- and imaging-based single-cell metabolic profiling.

Research interests

IMMUNOMETABOLISM

Our research aims to explain how metabolic reprogramming regulates macrophage subsets in different settings, focusing on cancer and cardiovascular disease. By unravelling key questions in macrophage immunometabolism, our overall goal is to demonstrate whether and how targeting macrophage metabolism could be used for future therapy.

Our distinct research lines investigate how metabolic enzymes like ATP Citrate Lyase and (immuno)metabolites like succinate and itaconate control macrophage responses and disease progression.

 

TEAM

Xanthe van Dierendonck works as a postdoc on an NWO ENW-Klein-funded project investigating the regulation and function of a newfound immunometabolite in macrophages. 

Sanne Verberk’s PhD aims to target immunometabolic circuits in atherosclerotic macrophages to improve their function and disease outcome. This work is funded by a Netherlands Heart Foundation senior researcher grant.

Kyra de Goede is funded by a CCA (Cancer Center Amsterdam) PhD grant and studies macrophage immunometabolism and immunometabolites in the tumor microenvironment.

Karl Harber is appointed on a ACS (Amsterdam Cardiovascular Sciences) PhD grant and investigates immunometabolites in the context of atherosclerosis in collaboration with Prof. Menno de Winther and Michel van Weeghel at AMC.

Elisa Meinster is research technician in our group and supports distinct research lines investigating how metabolic alterations in macrophages drive their function and disease outcome. Elisa is funded by a CCA Proof-of-concept grant and an European ERA-CVD consortium grant.

Frederike "Rike" Gorki is a PhD of Eicke Latz (University of Bonn) and performs her collaborative project on metabolic features that control atherosclerosis in our group in Amsterdam.

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or
If you made any changes in Pure these will be visible here soon.